2003
DOI: 10.1016/s1071-9164(03)00559-1
|View full text |Cite
|
Sign up to set email alerts
|

Safety and efficacy of intermittent, short-term, outpatient nesiritide infusions for the treatment of decompensated heart failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
6
0

Year Published

2004
2004
2006
2006

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 0 publications
0
6
0
Order By: Relevance
“…38 ICG has demonstrated value in therapeutic management with pacemaker optimization, 39 β blocker titration, 40 and in documenting hemodynamic stability and improvement with intravenous nesiritide administration. 41,42 This evidence, along with familiarity of invasive hemodynamic parameters and positive anecdotal experiences with ICG, has prompted some comprehensive HF management programs to incorporate ICG measurements into their care pathways for both chronic and acute HF. 43 In our study, significant changes in pharmacologic and device therapy occurred from baseline to final measurement.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…38 ICG has demonstrated value in therapeutic management with pacemaker optimization, 39 β blocker titration, 40 and in documenting hemodynamic stability and improvement with intravenous nesiritide administration. 41,42 This evidence, along with familiarity of invasive hemodynamic parameters and positive anecdotal experiences with ICG, has prompted some comprehensive HF management programs to incorporate ICG measurements into their care pathways for both chronic and acute HF. 43 In our study, significant changes in pharmacologic and device therapy occurred from baseline to final measurement.…”
Section: Discussionmentioning
confidence: 99%
“…Prognostic value has been shown in advanced HF in profiling survivors vs. nonsurvivors 37 and in association with need for hospitalization 38 . ICG has demonstrated value in therapeutic management with pacemaker optimization, 39 β blocker titration, 40 and in documenting hemodynamic stability and improvement with intravenous nesiritide administration 41,42 . This evidence, along with familiarity of invasive hemodynamic parameters and positive anecdotal experiences with ICG, has prompted some comprehensive HF management programs to incorporate ICG measurements into their care pathways for both chronic and acute HF 43…”
Section: Discussionmentioning
confidence: 99%
“…A number of small studies have reported that nesiritide can be used safely in the outpatient setting as an intermittent, short-term infusion (13)(14)(15). The FUSION trial randomized 210 patients with NYHA class III/IV heart failure to standard care (which could include intermittent inotropes) or outpatient nesiritide infusions (16).…”
Section: Nesiritide Use In Ambulatory and Ed Patientsmentioning
confidence: 99%
“…We will discuss these trials, briefly cover a few other nesiritide studies, and give our recommendations regarding nesiritide use in the ED. Other analyses of nesiritide, including a preliminary study vs. placebo (10) and several presentations in abstract form only, may have potential information applicable to the ED and will be discussed briefly as well (11)(12)(13)(14)(15)(16)(17)(18)(19).…”
Section: Introductionmentioning
confidence: 99%
“…Mulki et al 36 reported on a casecontrolled study of 16 patients treated with nesiritide for symptoms of recurrent volume overload following HF discharge, despite increased oral or IV diuretic therapy. Patients were treated weekly with nesiritide infusions for an average of 4.8 treatments and followed for 3–58 weeks after the last infusion.…”
mentioning
confidence: 99%